Comparison of Complement Factors and Genetic Polymorphisms of AMD Between Patients With Systemic Lupus Erythematosus (SLE) With and Without Retinal "Pseudo-drusen-like" Deposits: Case-control Study (PL-AMD)
PL-AMD
1 other identifier
observational
42
1 country
1
Brief Summary
The rationale of this research is to determine if patients with lupus and presenting retinal "pseudo-drusen-like" deposits have genetic and complement-related similarities with AMD patients. Based on the results obtained, this study could lead to future research that could better target the treatment of patients with lupus or patients with AMD (Age related Macular Degeneration). The primary objective is to check if patients with lupus, treated or not with antimalarial drugs, with "pseudo-drusen-like" deposits have a different complement profile (functional exploration of complement, complement factors, genetic complement polymorphisms involved in AMD) compared to patients without "pseudo-drusen-like" deposits.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Apr 2018
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 5, 2018
CompletedFirst Submitted
Initial submission to the registry
April 6, 2018
CompletedFirst Posted
Study publicly available on registry
April 20, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 15, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
May 15, 2021
CompletedMay 24, 2021
May 1, 2021
3.1 years
April 6, 2018
May 21, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Comparison of AMD genetic polymorphisms between case and control patients
Baseline
Comparison of complement factors between case and control patients
Baseline
Study Arms (2)
Case (with pseudo-drusen-like deposits)
Patients with lupus, treated or not with antimalarial drugs, with "pseudo-drusen-like" deposits
Control (without pseudo-drusen-like deposits)
Patients with lupus, treated or not with antimalarial drugs, without "pseudo-drusen-like" deposits
Interventions
Blood test for complement factors and genetic polymorphisms of AMD analysis
Eligibility Criteria
Patients with lupus, treated or not with APS, with ou without "pseudo-drusen-like" deposits
You may qualify if:
- Systemic lupus erythematosus
- Case patients : with "pseudo-drusen-like" deposit
- Control patients : without "pseudo-drusen-like" deposit
You may not qualify if:
- Patient under a measure of legal protection
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Fondation ophtalmologique Adolphe de Rothschild
Paris, 75019, France
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Martine MAUGET FAYSSE
Fondation Ophtalmologique A. de Rothschild
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- NETWORK
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 6, 2018
First Posted
April 20, 2018
Study Start
April 5, 2018
Primary Completion
May 15, 2021
Study Completion
May 15, 2021
Last Updated
May 24, 2021
Record last verified: 2021-05